An American College of Cardiology scientific statement emphasizes that exercise should be prescribed as a core component of cardiovascular disease (CVD) prevention and management, with the greatest absolute benefits occurring when physically inactive individuals begin exercising. The statement provides practical guidance for tailoring aerobic, resistance, balance, and flexibility training to individuals across the spectrum of cardiovascular health and disease, including coronary artery disease, peripheral artery disease, heart failure, cardiomyopathies, high blood pressure, obesity, adult congenital heart disease, and older age. It highlights the importance of cardiac rehabilitation through supervised, home-based, hybrid, and virtual programs, and discusses the role of exercise testing in assessing safety, guiding exercise intensity, and monitoring progress, while noting that routine preparticipation testing is unnecessary for most asymptomatic individuals. Wearable devices and digital tools can support self-monitoring, goal setting, and rehabilitation, but equitable access and digital literacy must be considered. Key priorities include integrating physical activity counseling into routine CVD care, improving clinician training, and individualizing exercise prescriptions according to patients’ goals and functional capacity. Further research is needed to improve long-term adherence, clinical outcomes, and scalable delivery. Source: https://www.jacc.org/
Targeting a systolic blood pressure (BP) of less than 120 mm Hg lowered the incidence…
In patients with type 2 diabetes (T2D) and high cardiovascular risk, targeting a systolic blood…
Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuing…
Two randomized, placebo-controlled trials of targeted therapies—ziltivekimab, a monoclonal antibody neutralizing interleukin-6, and pelacarsen, an…
Among US Medicare beneficiaries, colder ambient temperatures were associated with increased heart failure hospitalizations while…
In the 10-year extended follow-up of the DECISION-CTO trial, an initial strategy of percutaneous coronary…
This website uses cookies.